ARTICLE | Clinical News

IW001: Phase I started

November 1, 2010 7:00 AM UTC

ImmuneWorks began an open-label, U.S. Phase I trial to evaluate once-daily 0.1, 0.5 and 1 mg doses of oral IW001 for 24 weeks in 30 patients. IW001 has Orphan Drug designation in the U.S. for the indi...